Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-label Phase I Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamic Profile of a Single Dose of CS-101 Injection in Subjects With β-thalassemia Major

NCT06291961 is registered in ClinicalTrials.gov with CorrectSequence Therapeutics Co., Ltd as lead sponsor.

NCT NCT06291961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06291961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-label Phase I Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamic Profile of a Single Dose of CS-101 Injection in Subjects With β-thalassemia Major
Lead sponsor
CorrectSequence Therapeutics Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
April 18, 2024
Completion date
November 17, 2025
Enrollment
9 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

beta-thalassemia major